Innate Pharma S.A. (IPHA)
Innate Pharma S.A. (IPHA) Stock Price, Analysis & Data
| Bid | 2.19 |
| Market Cap | 196.45M |
| Revenue (ttm) | 9.01M |
| Net Income (ttm) | -49.18M |
| Beta | 0.86 |
| EPS (ttm) | -0.64 |
| PE Ratio (ttm) | n/a |
| Forward PE | -3.32 |
| P/B (ttm) | -7.81 |
| P/S (ttm) | 21.82 |
| Earnings Date | Sep 17, 2026 |
| Ask | 2.18 |
| Volume | 17,399 |
| Avg. Volume (20D) | 151,122 |
| Open | 2.11 |
| Previous Close | 2.07 |
| Day's Range | 2.09 - 2.13 |
| 52-Week Range | 1.17 - 2.71 |
| Analyst | Strong Buy |
| Price Target | 7.5 (258.85%) |
| Dividends | n/a |
| Ex-Dividend Date | n/a |
About IPHA
Innate Pharma S.A. operates as a biotechnology company that develops immunotherapies for cancer patients in France and internationally. The company's products include Lacutamab (IPH4102), an anti-KIR3DL2 antibody, which is in Phase II clinical trials for the treatment of cutaneous T-cell and peripheral T-cell lymphoma; IPH4502, a novel and differentiated topoisomerase I inhibitor ADC conjugated to exatecan targeting Nectin-4; and Monalizumab, a d...
Financial Performance
In 2025, Innate Pharma S.A.'s revenue was 2.79M, a decrease of -77.92% compared to the previous year's 12.62M. Earnings were -49.18M, a decrease of -0.59%.
Financial StatementsAnalyst Forecast
According to 4 analyst ratings, the average rating for IPHA stock is "Strong Buy". The 12-month stock price forecast is 7.5, which is upside of 258.85% from the latest price.
Stock ForecastsEarnings Surprise
Analysts project revenue of ... Upgrade
